Kelt, first AMBS sent out a press release that they were not going to release test results because they felt that it was "in the best interests of our shareholders" to wait and release it at the conference. Then they hastily arranged an appearance at an investors' conference the next day to present their case. The presenter is one of the founders of AMGEN, who says that AMBS's drug MANF is "one of the most exciting" drugs he's seen.

The bashers predictably claim that deferring the report on results is because they are bad. Of course that is absurd, if the results were bad they certainly wouldn't be presenting them at a major conference.